irinotecan has been researched along with glutamine in 8 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 6 (75.00) | 29.6817 |
2010's | 2 (25.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Al-Zoubi, A; Boucher, J; Savarese, D | 1 |
Ando, M; Hanioka, N; Ishida, S; Jinno, H; Nishimura, T; Ozawa, S; Saeki, M; Saito, Y; Sawada, J; Tanaka-Kagawa, T | 1 |
Ansari, R; Cheng, L; Helft, P; Juliar, B; Loehrer, P; Pan, CX; Pletcher, W; Seitz, D; Sweeney, C; Vinson, J | 1 |
Baracos, VE; Dieleman, LA; Field, CJ; Sawyer, MB; Xue, H | 1 |
Baracos, VE; Dieleman, LA; Field, CJ; Murray, D; Sawyer, MB; Xue, H | 1 |
Baracos, VE; Dieleman, LA; Field, CJ; Le Roy, S; Sawyer, MB; Xue, H | 1 |
1 review(s) available for irinotecan and glutamine
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for irinotecan and glutamine
Article | Year |
---|---|
A phase II trial of irinotecan, 5-fluorouracil and leucovorin combined with celecoxib and glutamine as first-line therapy for advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Celecoxib; Colorectal Neoplasms; Cyclooxygenase Inhibitors; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Glutamine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Pyrazoles; Sulfonamides; Treatment Outcome | 2005 |
6 other study(ies) available for irinotecan and glutamine
Article | Year |
---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Glutamine for irinotecan diarrhea.
Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Diarrhea; Female; Glutamine; Humans; Irinotecan; Male; Middle Aged; Rectal Neoplasms | 2000 |
Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38), an active metabolite of irinotecan (CPT-11), by human UGT1A1 variants, G71R, P229Q, and Y486D.
Topics: Amino Acid Substitution; Animals; Arginine; Aspartic Acid; Camptothecin; Chlorocebus aethiops; COS Cells; Genetic Variation; Glucuronides; Glucuronosyltransferase; Glutamine; Glycine; Humans; Irinotecan; Proline; Tyrosine | 2003 |
Nutritional modulation of antitumor efficacy and diarrhea toxicity related to irinotecan chemotherapy in rats bearing the ward colon tumor.
Topics: Animals; Camptothecin; Colonic Neoplasms; Diarrhea; Diet; Fatty Acids, Omega-3; Female; Food-Drug Interactions; Glutamine; Irinotecan; Oligosaccharides; Probiotics; Rats | 2007 |
Bolus oral glutamine protects rats against CPT-11-induced diarrhea and differentially activates cytoprotective mechanisms in host intestine but not tumor.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Camptothecin; Colon; Colonic Neoplasms; Cytoprotection; Diarrhea; Female; Glutamine; Irinotecan; Neoplasms, Experimental; Rats | 2008 |
Single and combined supplementation of glutamine and n-3 polyunsaturated fatty acids on host tolerance and tumour response to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin (CPT-11)/5-fluorouracil chemotherapy in rats bearing Ward colo
Topics: Animals; Antineoplastic Agents, Phytogenic; Body Weight; Camptothecin; Colonic Neoplasms; Combined Modality Therapy; Diarrhea; Dietary Supplements; Fatty Acids, Omega-3; Female; Fluorouracil; Glutamine; Immune Tolerance; Irinotecan; Leukocyte Count; Nutritional Status; Rats; Rats, Inbred F344; Treatment Failure; Xenograft Model Antitumor Assays | 2009 |